| FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer T Conroy, P Hammel, M Hebbar, M Ben Abdelghani, AC Wei, JL Raoul, ... New England Journal of Medicine 379 (25), 2395-2406, 2018 | 2763 | 2018 |
| Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up A Vogel, A Cervantes, I Chau, B Daniele, JM Llovet, T Meyer, JC Nault, ... Annals of Oncology 29, iv238-iv255, 2018 | 1016 | 2018 |
| Cutaneous side-effects of kinase inhibitors and blocking antibodies C Robert, JC Soria, A Spatz, A Le Cesne, D Malka, P Pautier, J Wechsler, ... The lancet oncology 6 (7), 491-500, 2005 | 702 | 2005 |
| Risk of pancreatic adenocarcinoma in chronic pancreatitis D Malka, P Hammel, F Maire, P Rufat, I Madeira, F Pessione, P Levy, ... Gut 51 (6), 849-852, 2002 | 654 | 2002 |
| Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study COVIDSurg Collaborative Anaesthesia 76 (6), 748-758, 2021 | 597* | 2021 |
| The global burden of cancer 2013 Global Burden of Disease Cancer Collaboration JAMA oncology 1 (4), 505, 2015 | 552* | 2015 |
| Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study J Edeline, M Benabdelghani, A Bertaut, J Watelet, P Hammel, JP Joly, ... Journal of Clinical Oncology 37 (8), 658-667, 2019 | 505 | 2019 |
| Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a … RK Kelley, M Ueno, C Yoo, RS Finn, J Furuse, Z Ren, T Yau, HJ Klümpen, ... The Lancet 401 (10391), 1853-1865, 2023 | 497 | 2023 |
| Risk factors for diabetes mellitus in chronic pancreatitis D Malka, P Hammel, A Sauvanet, P Rufat, D O'Toole, P Bardet, J Belghiti, ... Gastroenterology 119 (5), 1324-1332, 2000 | 478 | 2000 |
| Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial D Malka, P Cervera, S Foulon, T Trarbach, C de la Fouchardière, ... The lancet oncology 15 (8), 819-828, 2014 | 435 | 2014 |
| Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE‐158 and KEYNOTE‐028 studies SA Piha‐Paul, DY Oh, M Ueno, D Malka, HC Chung, A Nagrial, RK Kelley, ... International journal of cancer 147 (8), 2190-2198, 2020 | 425 | 2020 |
| Are G3 ENETS neuroendocrine neoplasms heterogeneous FL Vélayoudom-Céphise, P Duvillard, L Foucan, J Hadoux, CN Chougnet, ... Endocr Relat Cancer 20 (5), 649-57, 2013 | 391 | 2013 |
| Midterm Local Efficacy and Survival after Radiofrequency Ablation of Lung Tumors with Minimum Follow-up of 1 Year: Prospective Evaluation1 T Baère, J Palussière, A Aupérin, A Hakime, M Abdel-Rehim, M Kind, ... Radiology 240 (2), 587-596, 2006 | 388 | 2006 |
| Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆ A Vogel, J Bridgewater, J Edeline, RK Kelley, HJ Klümpen, D Malka, ... Annals of Oncology 34 (2), 127-140, 2023 | 351 | 2023 |
| Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect D Elias, G Liberale, D Vernerey, M Pocard, M Ducreux, V Boige, D Malka, ... Annals of surgical oncology 12, 900-909, 2005 | 348 | 2005 |
| Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? D Goéré, D Malka, D Tzanis, V Gava, V Boige, C Eveno, L Maggiori, ... Annals of surgery 257 (6), 1065-1071, 2013 | 286 | 2013 |
| Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer M Barret, S Antoun, C Dalban, D Malka, T Mansourbakht, A Zaanan, ... Nutrition and cancer 66 (4), 583-589, 2014 | 280 | 2014 |
| Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis D Elias, C Honoré, F Dumont, M Ducreux, V Boige, D Malka, P Burtin, ... Annals of surgery 254 (2), 289-293, 2011 | 270 | 2011 |
| Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification—preliminary results N Lassau, S Koscielny, L Chami, M Chebil, B Benatsou, A Roche, ... Radiology 258 (1), 291-300, 2011 | 255 | 2011 |
| An update on treatment options for pancreatic adenocarcinoma A Lambert, L Schwarz, I Borbath, A Henry, JL Van Laethem, D Malka, ... Therapeutic advances in medical oncology 11, 1758835919875568, 2019 | 250 | 2019 |
Michel DucreuxUniversité Paris-Saclay, Gustave RoussyVerified email at gustaveroussy.fr